Some AMPs can exploit both differences in membrane charge and cell stability to specifically target certain cancer cells (Rathinakumar et al., 2009; Mahlapuu et al., 2016; Wang et al., 2017), suggesting that these peptides are potential new anti-cancer agents and encouraging further development of other classes of AMPs in this area. This evidence concerns the gene ADSL and cancer.